We are live on ! Find out more
CMMB

Chemomab Therapeutics
CMMB

15 hedge funds and large institutions have $2.68M invested in Chemomab Therapeutics in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

0% less ownership

Funds ownership: 0.36% → 0.36% (-0%)

6% less funds holding

Funds holding: 16 → 15 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

83% less capital invested

Capital invested by funds: $15.9M → $2.68M (-$13.2M)

Holders
15
Holders Change
-1
Holders Change %
-6.25%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ASN
Advisory Services Network
Georgia
+$38.9K
2
Morgan Stanley
Morgan Stanley
New York
+$19.5K
3
Envestnet Asset Management
Envestnet Asset Management
Illinois
+$4.82K
4
State Street
State Street
Massachusetts
+$2.7K
5
Osaic Holdings
Osaic Holdings
Arizona
+$2.03K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$134K
2
AIM
ARK Investment Management
Florida
-$4K
3
JP Morgan Chase
JP Morgan Chase
New York
-$4K
4
UBS Group
UBS Group
Switzerland
-$4K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$42
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$1.07M – – –
IC
2
Ikarian Capital
Texas
$992K – – –
BFM
3
Boothbay Fund Management
New York
$153K – – –
State Street
4
State Street
Massachusetts
$134K +$2.7K +194 +2%
MIH
5
Meitav Investment House
Israel
$129K – – –
Envestnet Asset Management
6
Envestnet Asset Management
Illinois
$45K +$4.82K +346 +13%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$43K – – –
ASN
8
Advisory Services Network
Georgia
$41K +$38.9K +2,793 New
Osaic Holdings
9
Osaic Holdings
Arizona
$29K +$2.03K +146 +8%
Morgan Stanley
10
Morgan Stanley
New York
$21K +$19.5K +1,399 New
UWM
11
Urban Wealth Management
California
$10K +$9.63K +691 New
O
12
OrbiMed
New York
$9.54K – – –
NFSG
13
Newbridge Financial Services Group
Florida
$4K – – –
Royal Bank of Canada
14
Royal Bank of Canada
Ontario, Canada
$1K -$42 -3 -5%
CAPTRUST Financial Advisors
15
CAPTRUST Financial Advisors
North Carolina
$1K – – –
Renaissance Technologies
16
Renaissance Technologies
New York
– -$134K -6,990 Closed
UBS Group
17
UBS Group
Switzerland
– -$4K -221 Closed
AIM
18
ARK Investment Management
Florida
– -$4K -198 Closed
JP Morgan Chase
19
JP Morgan Chase
New York
– -$4K -188 Closed

CMMB Hedge Fund Activity: Q2 2022 in Review

15 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q2 2022, worth a combined $2.68M — down 83% from $15.9M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of CMMB and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.

The largest buyer was Advisory Services Network, opening a new position worth an estimated $38.9K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $134K sold.

  • 15 institutional investors held Chemomab Therapeutics (CMMB) as of Q2 2022, down from 16 in Q1 2022.
  • Funds reported $2.68M of Chemomab Therapeutics stock for Q2 2022, down 83% quarter-over-quarter.
  • 3 funds opened new Chemomab Therapeutics positions in Q2 2022 and 4 closed out, a net change of -1 holder.
  • The largest Chemomab Therapeutics buyer in Q2 2022 was Advisory Services Network, an estimated $38.9K added.
  • The largest Chemomab Therapeutics seller in Q2 2022 was Renaissance Technologies, an estimated $134K sold.

Based on aggregated 13F filings for Q2 2022.